Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Shanghai S.E.
Equities
600332
CNE000001733
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31.25 CNY | -0.22% | +1.79% | +9.27% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The stock, which is currently worth 2024 to 0.18 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.27% | 6.65B | - | ||
+25.00% | 556B | B | ||
-6.33% | 354B | C+ | ||
+19.90% | 331B | B- | ||
+7.95% | 296B | C+ | ||
+13.45% | 233B | B+ | ||
+5.61% | 201B | B- | ||
-10.22% | 193B | A+ | ||
-12.26% | 143B | C+ | ||
-6.47% | 144B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 874 Stock
- 600332 Stock
- Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited